Aktienanalyse zu Haleon PLC (HLN)HLNHaleon PLC

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and others. The Company's segments include North America, Europe, Asia Pacific, and International. Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban. It operates in the Healthcare sector (PERFUMES, COSMETICS, AND OTHER TOILET PREPARATIONS industry).

Haleon PLC (HLN) appears to be a good buy right now, trading at $9.32 with a forward P/E of 15.70, which is reasonable compared to its industry peers. The recent 5-day price change of +5.91% indicates positive momentum, while the RSI of 69.96 suggests it is approaching overbought territory but still has room to grow. The main risk is the downgrade by Rothschild & Co Redburn, which could affect investor sentiment, but the overall bullish hedge fund activity, increasing by 142.48%, suggests confidence in the stock's future performance.